

Studies on Absorption and Emission Characteristics of Inclusion Complexes of Some 4-Arylidenamino-5-phenyl-4H-1, 2, 4-triazole-3-thiols

Sunakar Panda¹ · Sashikanta Nayak¹

Received: 6 September 2015 / Accepted: 16 November 2015 / Published online: 21 November 2015
© Springer Science+Business Media New York 2015

Abstract The inclusion complexes of a series of 4-arylidenamino-5-phenyl-4H-1, 2, 4-triazole-3-thiols have been prepared with β -cyclodextrin. The compounds and their inclusion complexes have been characterized by studying their physical and spectral properties. The thermodynamic stability constant and free energy of activation have been determined to know the stability of inclusion complexes and type of host-guest relation. Finally, absorption, excitation and emission spectra of the compounds (4-arylidenamino-5-phenyl-4H-1, 2, 4-triazole-3-thiols) and their inclusion complexes have been taken. It is found that inclusion complex formation brings about a drastic change in absorption and fluorescence characteristic (both excitation and emission spectra) of newly synthesized compounds.

Keywords Triazole-3-thiol · Inclusion complex · Absorption spectra · Excitation spectra · Emission spectra

Introduction

Fluorescence characteristics of fluorophores depend upon a number of environmental factors including interactions between the fluorophore and surrounding solvent molecules (dictated by solvent polarity), other dissolved inorganic and organic compounds, temperature, pH, and the localized concentration of the fluorescent species. The effects of these parameters vary widely from one fluorophore to another. The

excitation and emission spectra as well as quantum yields, can be heavily influenced by environmental variables. In fact, the high degree of sensitivity in fluorescence is primarily due to interactions that occur in the local environment during the excited state life time [1–7].

The drugs containing 1, 2, 4-triazole nucleus are reported to exhibit a wide spectrum of pharmacological activities like antimicrobial [8–12], anticancer [13, 14], antiviral [15], anti-inflammatory [16], analgesic [17], anticonvulsant [18] etc. It is known that the formation of inclusion complex of drug molecules with β -cyclodextrin improves their solubility, stability as well as bioavailability [19–24]. But transference of drug molecules which are usually nonpolar in nature, in to hydrophobic core of β -cyclodextrin causes a drastic change in its microenvironment. Since the spectral characteristics of molecules depend upon the molecular structure and its microenvironment [6, 7] such a transference will definitely have some impact on fluorescence characteristics of the molecules.

In view of these facts, an attempt has been made to synthesize some 4-arylidenamino-5-phenyl-4H-1,2,4-triazole-3-thiol (Schiff bases) in their purest forms and prepare their inclusion complexes with β -cyclodextrin. The absorption, excitation and emission spectra of the compounds and their inclusion complexes are taken to examine whether the inclusion complex formation has any impact on absorption and emission characteristics of 4-arylidenamino-5-phenyl-4H-1, 2, 4-triazole-3-thiols.


Experimental

Materials and Methods

All the chemicals used in the present work were procured from local market. Double distilled water was used as solvent.

✉ Sunakar Panda
sunakar_panda@yahoo.com


¹ P.G. Department of Chemistry, Berhampur University, Bhanjabihar, Odisha 760007, India



Scheme 1 A: 4-Benzilidenamino -5-phenyl-4*H*-1, 2, 4-triazole-3-thiol. B: 4-[2-Nitrobenzilidenamino] -5-phenyl-4*H*-1,2,4-triazole-3-thiol. C: 4-[4-Bromobenzilideneamino] -5-phenyl-4*H*-1, 2, 4-triazole-3-thiol. D: 4-[4-Methoxybenzilideneamino] -5-phenyl-4*H*-1, 2, 4-triazole-3-thiol.

E: 4-[2-Hydroxybenzilideneamino] -5-phenyl-4*H*-1, 2, 4-triazole-3-thiol. F: 4-[(furan-2-yl)methyleneamino] -5-phenyl-4*H*-1, 2, 4-triazole-3-thiol

Fig. 1 Phase solubility study of the synthesized compounds in aqueous solution of β -cyclodextrin



The elemental analysis was performed in a CHN analyzer. Melting points were recorded by open capillary method. Absorption spectra were recorded in Shimadzu UV-1800 spectrophotometer and IR spectra were recorded in KBr pellets in Shimadzu 8400 FT-IR spectrophotometer. ^1H NMR spectra were obtained with Brukers spectrophotometer model ultra-shield at 300 MHz in DMSO- d_6 solution with TMS as internal standard. The purity of the newly synthesized compounds were checked by TLC. Fluorescence emission and excitation spectra were recorded in a Shimadzu RF-1501 spectrofluorimeter equipped with a150W xenon lamp. The synthesis of the titled compounds A, B, C, D, E and F were carried out as per Panda et al. 2015 [24] as shown in Scheme 1.

Phase Solubility Measurements

The aqueous phase solubility of the compounds at various concentrations of β -cyclodextrin (0–10 mM) was studied by Higuchi-Conner method [25].

Synthesis of Inclusion Complexes

Co-precipitation method was used for the preparation of inclusion complexes of the compounds with β -cyclodextrin [22, 26].

Study of Thermodynamic Properties

The thermodynamic stability constants of the complexes were calculated from plot of inverse of change in absor-

bance versus inverse concentration of β -cyclodextrin using Benesi-Hilderband relation [27].

$$1/\Delta A = 1/\Delta \epsilon + 1/K' \cdot \Delta \epsilon [\text{Guest}]_0 \cdot [\beta\text{-CD}]$$

where ΔA is change in absorbance, $\Delta \epsilon$ is change in absorption coefficient, K is stability constant, $[\text{Guest}]_0$ is the concentration of compound and $[\beta\text{-CD}]$ is the concentration of β -cyclodextrin. The values of K for all the complexes are calculated using the relation

$$K = \text{Intercept/Slope}$$

The value of ΔG at 298 K was calculated using the equation:

$$\Delta G = -RT \ln K$$

Results and Discussion

Six different 4-arylidenamino-5-phenyl-4 H-1, 2, 4-triazole-3-thiols (A, B, C, D, E and F) have been synthesized (as shown in scheme 1) in their purest forms. The inclusion complexes of A, B, C, D, E and F have been prepared with β -cyclodextrin (β -CD) after determining the optimum concentration of host and guest through aqueous phase solubility study (Fig. 1). The structures of the compounds (A, B, C, D, E and F) have been confirmed from the study of their physical properties, elemental composition, FT-IR and ^1H NMR data (Tables 1 and 2). The elemental


Table 1 Some physical properties of the synthesized compounds and their inclusion complexes

Sl No.	Compound/Complex	Molecular formula	Molecular weight	Colour	M.P. (°C)	Yield(%)
1	Compound- A	$\text{C}_{15}\text{H}_{12}\text{N}_4\text{S}$	280.35	Light brown	180–185	73
	I.C.A			white	272–274	75
2	Compound- B	$\text{C}_{15}\text{H}_{11}\text{N}_5\text{O}_2\text{S}$	325.35	Pale yellow	170–172	72
	I.C.B			Dull white	282–285	74
3	Compound- C	$\text{C}_{15}\text{H}_{11}\text{BrN}_4\text{S}$	359.24	Light yellow	178–180	77
	I.C.C			white	275–280	77
4	Compound- D	$\text{C}_{16}\text{H}_{14}\text{N}_4\text{OS}$	310.37	Dull White	160–162	71
	I.C.D			white	280–285	77
5	Compound- E	$\text{C}_{15}\text{H}_{12}\text{ON}_4\text{S}$	296.35	Dull white	145–148	71
	I.C.E			white	278–280	75
6	Compound- F	$\text{C}_{13}\text{H}_{10}\text{N}_4\text{OS}$	270.31	Dark gray	170–175	73
	I.C.F			white	281–283	77

Table 2 Spectral data and elemental composition of the compounds and their inclusion complexes

Sl No.	Compound/ name	IR (KBr) cm^{-1} case	NMR(DMSO- d_6)	Elemental Analysis Calculated (Found)		
				C	H	N
1	A	968.27 (N-C-S str), 3034.03, 3099.61, (Ar-H str), 1498.69 (C = C _{str}), 696.38 (C-S str), 1350.17 (C-N str), 0.1610.56 (C = N _{str})	7.52–7.90 (m, 10 H, Ar-H), 14.25 (s, 1 H, SH), 9.70 (s, 1 H, N = CH).	64.26 (64.46)	4.31 (4.02)	19.98 (19.92)
	I.C.A	937.4 (N-C-S str), 2931.80 (Ar-H str), 1409.96 (C = C _{str}), 756.10 (C-S str), 1332.81 (C-N str), 0.1656.85 (C = N _{str}), 3398.57 (OHstr, β -CD), 2931.80 (C-Hstr, β -CD)	7.32–7.91 (m, 10 H, Ar-H), 3.35 (s, 1 H, β -CD), 3.43 (s, 1 H, β -CD), 3.45 (s, 1 H, β -CD), 3.57 (s, 1 H, β -CD), 3.59 (s, 1 H, β -CD)			
2	B	943.27 (N-C-S str), 3115.04 (Ar-H str), 696.30 (C-S str), 1498.69 (C = C _{str}), 1342.46 (C-N str), 1529.55, 1342.46 (NO ₂), 1610 (C = N _{str})	7.53–8.34 (m, 9 H, ArH), 14.304 (s, 1 H, SH), 10.499 (s, 1 H, N = CH.)	55.37 (55.27)	3.41 (3.32)	21.53 (21.50)
	I.C.B	937.40 (N-C-S str), 2933.80 (Ar-H str), 1409.96 (C = C _{str}), 704.02 (C-S str), 1361.74 (C-N str), 0.1409.96 (NO ₂), 1658.78 (C = N _{str}), 3367.71 (OHstr, β -CD), 2931.80 (C-Hstr, β -CD)	7.92–8.13 (m, 9 H, Ar-H), 3.37 (s, 1 H, β -CD), 3.61 (s, 1 H, β -CD), 3.63 (s, 1 H, β -CD), 3.64 (s, 1 H, β -CD), 3.66 (s, 1 H, β -CD),			
3	C	968.27 (N-C-S str), 2941.44, 3113.11 (Ar-H str), 1500.62 (C = C _{str}), 684.73 (C-S str), 1355.96 (C-N str), 0.1510.56 (C = N _{str}), 609.51 (C-Br)	7.54–7.89 (m, 9 H, Ar-H),	50.15 (50.19)	03.09 (3.14)	15.60 (15.51)
	I.C.C	937.40 (N-C-S str), 2931.80 (Ar-H str), 1409.96 (C = C _{str}), 756.10 (C-S str), 1332.81 (C-N str), 0.1658.78 (C = N _{str}), 3385.07 (OHstr, β -CD), 2931.80 (C-Hstr, β -CD), 613.36 (C-Br)	7.36–7.96 (m, 9 H, Ar-H), 3.35 (s, 1 H, β -CD), 3.42 (s, 1 H, β -CD), 3.46 (s, 1 H, β -CD), 3.54 (s, 1 H, β -CD), 3.58 (s, 1 H, β -CD)			
4	D	943.19 (N-C-S str), 3076.46, 3115.04 (Ar-H str), 1500.62 (C = C _{str}), 696.30 (C-S str), 1352.10 (C-N str), 1598.99 (C = N _{str})	7.04–8.62 (m, 9 H, Ar-H), 3.82–3.85 (s, 3 H, OCH ₃)	61.92 (61.95)	04.55 (4.52)	18.05 (18.01)
	I.C.D	937.40 (N-C-S str), 2931.80, (Ar-H str), 1409.96 (C = C _{str}), 756.10 (C-S str), 1332.81, (C-N str), 0.3371.57 (OHstr, β -CD), 2912.51 (C-Hstr, β -CD)	7.94–8.78 (m, 9 H, Ar-H), 3.32 (s, 1 H, β -CD), 3.34 (s, 1 H, β -CD), 3.37 (s, 1 H, β -CD), 3.61 (s, 1 H, β -CD), 3.64 (s, 1 H, β -CD), 2.73–2.89 (s, 3 H, OCH ₃)			
5	E	941.26 (N-C-S str), 2951.09, 2993.52 (Ar-H str), 1446.61 (C = C _{str}), 696.30 (C-S str), 1350.17 (C-N str), 3134.33 (ArOH), 1610.56 (C = N _{str})	7.49–7.88 (m, 9 H, Ar-H), 8.98 (s, 1 H, OH)	60.79 (60.84)	4.08 (4.12)	18.91 (18.93)
	I.C.E	937.40 (N-C-S str), 2931.80 (Ar-H str), 1409.96 (C = C _{str}), 756.10 (C-S str), 1361.74 (C-N str), 1658.78 (C = N _{str}), 3365.78 (OHstr, β -CD), 3226.91 (Ar-OH), 3236.55, 3294.42 (C-Hstr, β -CD)	7.94–8.28 (m, 9 H, Ar-H), 3.34 (s, 1 H, β -CD), 3.54 (s, 1 H, β -CD), 3.57 (s, 1 H, β -CD), 3.62 (s, 1 H, β -CD), 4.46 (s, 1 H, β -CD)			
6	F	941.26 (N-C-S str), 3099.61, 3134.33 (Ar-H str), 1571.99, (C = C _{str}), 696.30 (C-S str), 1350.17 (C-N str), 1610.56 (C = N _{str})	6.78–8.06 (m, 8 H, ArH),	57.76 (57.64)	03.73 (3.76)	20.73 (20.70)
	I.C.F	937.40 (N-C-S str), 2931.80, (Ar-H str), 1656.85 (C = C _{str}), 705.95 (C-S str), 1361.74 (C-N str), 1653.00 (C = N _{str}), 3290.56.71 (OHstr, β -CD), 3167.12 (C-Hstr, β -CD)	7.95–8.23 (m, 8 H, Ar-H), 3.31 (s, 1 H, β -CD), 3.35 (s, 1 H, β -CD), 3.55 (s, 1 H, β -CD), 3.63 (s, 1 H, β -CD), 3.66 (s, 1 H, β -CD)			

Fig. 2 Plot of inverse absorbance against inverse concentration of β -cyclodextrin



composition of the compounds matches with theoretical data (Table 2). The FT-IR and ¹H NMR data of the compounds confirm the expected structures. The preparation of inclusion complexes of the compounds have been confirmed from the changes in melting point, colour and FT-IR and ¹H NMR spectral characteristics (Tables 1 and 2). The IR- stretching frequencies due to different bonds undergo downward shift towards lower energy and the peaks become broader, weaker and smoother. The ¹H NMR signals due to different protons undergo smaller shifts (small shift towards down field in case of all the compounds) after their inclusion complex formations. The changes in IR spectral characteristics may be attributed to the restriction on the compounds for undergoing vibration within the cavity of β -CD due to the development of weak interaction like H-bonding, vander-Waal forces and hydrophobic interactions etc. [22]. This observation clearly demonstrates transference of the compound from a more protic environment (aqueous media) to a less protic environment (cavity of β -CD). The compound and β -CD interaction leading to inclusion complex formation is further supported by ¹H NMR data (Table 2). The changes in the microenvironment of the compound after encapsulation may cause a small shift in ¹H NMR signals.

Table 3 Thermodynamic stability constant and free energy change of inclusion complexes

Sl.No.	Inclusion complex	Thermodynamic stability Constant (M ⁻¹)	ΔG (kJ/mol)
1	I.C.A	773.76	-16.478
2	I.C.B	685.37	-16.178
3	I.C.C	810.06	-16.592
4	I.C.D	194.91	-13.063
5	I.C.E	878.32	-16.793
6	I.C.F	330.21	-14.369

The aqueous phase-solubility diagrams of the compounds with β -cyclodextrin are shown in Fig. 1. It is seen that aqueous solubility of the compounds increases linearly as a function of the concentration of β -cyclodextrin up to 5th point followed by a decline. This clearly indicates that the concentration at 5th point is the optimum concentration for inclusion complex formation. The plot of inverse change in absorbance against inverse concentration of β -cyclodextrin gives straight lines with definite slope and intercept for different compounds (Fig. 2). The thermodynamic stability constants (K) have been calculated from the slope and intercept [27] and are found to be in the range of 194.91 to 878.32 (Table 3). Since all the values are remaining within ideal range [28] all the inclusion complexes formed are quite stable. Further, it is found that the values of all the slopes are less than one indicating the inclusion complexes to have 1:1 stoichiometry [21–23]. Negative

Table 4 Absorption, excitation and emission peak position of the compounds and their inclusion complexes

Sl. No.	Compound/Complex	Absorption maximum λ_{Max} (nm)	Excitation peak position λ (nm)	Emission peak position λ (nm)
1	Compound- A	294	299	448
	I.C.A	270	295	445
2	Compound- B	295	313	451
	I.C.B	275	286	437
3	Compound- C	295	326	453
	I.C.C	270	307	433
4	Compound- D	294	307	451
	I.C.D	278	294	445
5	Compound- E	294	294	449
	I.C.E	265	283	439
6	Compound- F	292	316	452
	I.C.F	287	303	439




Fig. 3 UV spectrum of β - cyclodextrin, compound A and its inclusion complex




Fig. 4 UV spectrum of β - cyclodextrin, compound B and its inclusion complex




Fig. 5 UV spectrum of β - cyclodextrin, compound C and its inclusion complex




Fig. 6 UV spectrum of β - cyclodextrin, compound D and its inclusion complex




Fig. 7 UV spectrum of β - cyclodextrin, compound E and its inclusion complex




Fig. 8 UV spectrum of β - cyclodextrin, compound F and its inclusion complex




Fig. 9 Excitation and emission spectra of compound A and its inclusion complex




Fig. 10 Excitation and emission spectra of compound B and its inclusion complex




Fig. 11 Excitation and emission spectra of compound C and its inclusion complex




Fig. 12 Excitation and emission spectra of compound D and its inclusion complex




Fig. 13 Excitation and emission spectra of compound E and its inclusion complex




Fig. 14 Excitation and emission spectra of compound F and its inclusion complex

values of free energy changes for all the inclusion complexes (Table 3) further suggest that the process of inclusion complex formation is spontaneous and thermodynamically allowed.

It is interesting to note that the absorption and emission characteristics of all the compounds (A, B, C, D, E and F) undergo drastic changes after their inclusion complex formation. The absorption maxima shifts towards lower wavelength (Table 4) and the intensity of the peaks becomes higher after their inclusion complex formation (Figs. 3, 4, 5, 6, 7, and 8). However, although the excitation and emission peaks shift towards lower wavelength, the intensity of the peaks becomes lower after their inclusion complex formation (Figs. 9, 10, 11, 12, 13, and 14). The shifting of absorption and excitation peak positions may be due to the fact that more amount of energy is required for the compounds for their excitation after encapsulation because the molecules get stabilized within the cavity of β -cyclodextrin through some weak intermolecular forces. The lowering of fluorescence intensity may be due to lesser population of molecules in the excited state than ground state.

Conclusion

The above results established the fact that the inclusion complexes of the synthesized compounds alter the absorption and emission characteristics of the molecules.

References

1. Ayman A, Shafi A, Shar S, Shihry AL (2009) Fluorescence enhancement of 1-naphthol-5-sulfonate by forming inclusion complex with β -cyclodextrin in aqueous solution. *Spectrochim Acta A Mol Biomol Spectrosc* 72(3):533–537
2. Muthu Vijayan Enoch IV, Swaminathan M (2004) Inclusion complexation of 2-amino-7-bromofluorene by β -cyclodextrin: spectral characteristics and the effect of pH. *J Fluoresc* 14:751–756
3. Wang R, Yuan L, Donal HM (2005) A green to blue fluorescence switch of protonated 2-aminoanthracene upon inclusion in cucurbit [7]uril. *Chem Commun* 47:5867–5869
4. Maafi M, Laassis B, Aaron JJ (1995) Photochemically induced fluorescence investigation of a β -cyclodextrin: azure A inclusion complex and determination of analytical parameters. *J Inclusion Phenom Mol Recognit Chem* 22:235–247
5. Misiuk W (2012) Spectrofluorimetric study on inclusion interaction of β -cyclodextrin with duloxetine and its analytical application. *Ind J Chem* 51A:1706–1710
6. Ahmed RM, Dani M, Elbashir AA (2013) Host–guest inclusion complex of β -cyclodextrin and cephalixin and its analytical application. *Int J Pharm Chem Res* 2:2278–2290
7. Nelson G, Patonay G, Warner IM (1988) Effects of selected alcohols on cyclodextrin inclusion complexes of pyrene using fluorescence lifetime measurements. *Anal Chem* 60:274–279
8. Shaker RM (2006) The chemistry of mercapto- and thione-substituted 1,2,4-triazole and their utility in heterocyclic synthesis. *ARKIVOC* 2006(ix):59–112
9. Bayrak H, Demirbas A, Demirbas N, Karaoglu SA (2009) Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities. *Eur J Med Chem* 44(11):4362–4366
10. Xu J, Cao Y, Zhang J (2011) Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives. *Eur J Med Chem* 46(7):3142–3148
11. Pintilie O, Profire L, Sunel V, Popa M, Pui A (2007) Synthesis and antimicrobial activity of some new 1,3,4-thiadiazole and 1,2,4-triazole compounds having a D, L-methionine moiety. *Molecules* 12:103–113
12. Bayrak H, Demirbas A, Karaoglu SA, Demirbas N (2009) Synthesis of some new 1,2,4-triazoles, their mannich and Schiff bases and evaluation of their antimicrobial activities. *Eur J Med Chem* 44:1057–1066
13. Holla BS, Veerandra B, Shivananda MK, Poojary B (2003) Synthesis characterization and anticancer activity studies on some mannich bases derived from 1,2,4-triazoles. *Eur J Med Chem* 38(7–8):759–767
14. Al-Soud YA, Al-Masoudi NA, AE-RS (2006) Ferwanah synthesis and properties of new substituted 1,2,4-triazoles: potential antitumor agents. *Bioorg Med Chem* 11:1701–1708
15. Abdel-Aal MT, El-Sayed WA, El-Kosy SM, El-Ashry ESH (2008) Synthesis and antiviral evaluation of novel 5-(N-arylaminoethyl-1,3,4-oxadiazol-2-yl)hydrazines and their sugars, 1,2,4-triazoles, tetrazoles and pyrazolyl derivatives. *Arch Pharm* 341(5):307–313
16. Labanauskas L, Udrenaitė E, Gaidelis P, Brukstus A (2004) Synthesis of 5-(2-,3- and 4-methoxyphenyl)-4 H-1,2,4-triazole-3-thiol derivatives exhibiting anti-inflammatory activity. *IFarmaco* 59(4):255–259
17. Labanauskas L, Kalcas V, Uderenaitė E, Gaidelis P, Brukstus A, Dauksas V (2001) Synthesis of 3-(3,4-dimethoxyphenyl)-1 H-1,2,4-triazole-5-thiol and 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole derivatives exhibiting anti-inflammatory activity. *Pharmazie* 56:617–619
18. Almasirad SA, Tabatabai M (2004) Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2-fluorophenoxy) phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles. *Bioorg Med Chem Lett* 14(24):6057–6059
19. Yang B, Lin J, Chen Y, Liu Y (2009) Artemether/hydroxypropyl- β -cyclodextrin host-guest system: characterization, phase-solubility and inclusion mode. *Bioorg Med Chem* 17:6311–6317
20. Panda S, Sahu R (2013) Studies on inclusion complex of 3-(2-chloro phenyl) 4-methyl 2- thiocarbamoyl-3,3a-dihydro pyrazolo[3,4c] pyrazole. *Am J Adv Drug Deliv* 1(5):1–9
21. Panda S, Sahu R (2014) Studies on inclusion complex of 4-methyl-3-phenyl-2- thiocarbamoyl-3,3a-dihydro pyrazolo[3,4c] pyrazole. *J Pharm Bio Sci* 9(2):30–36
22. Panda S, Singh DL (2014) Study of antioxidant, antimicrobial and anthelmintic properties of 1-nicotinoyl-4-aryl-3-methyl 3a,4-dihydropyrazolo [3,4c] pyrazoles and their inclusion complexes with β -cyclodextrin. *World J Pharm Pharma Sci* 3(4):1639–1654
23. Panda S, Singh DL, Sahu R (2013) Study of antioxidant properties of 1-nicotinoyl-4-aryl-3-methyl 3a,4-dihydropyrazole [3,4c] pyrazoles and their inclusion complexes with β -cyclodextrin. *Int J Chem Pharm Sci* 4(2):1–6
24. Panda S, Nayak S, Das PK (2015) Impact of inclusion complex formation on antioxidant activity of some 4-arylideno-5-phenyl-4h-1, 2, 4-triazole-3-thiols. *World J Pharm Pharma Sci* 4:939–951
25. Higuchi T, Connors K (1965) Phase -solubility technique. *Adv Anal Chem Instrum* 4:117–212
26. Ueda H, Endo T (2006) Large-ring cyclodextrins. In: Dodziuk H (ed) cyclodextrins and their complexes. Chemistry, analytical methods, applications. Wiley-VCH Verlag, Weinheim, pp. 370–380

27. Bensi HA, Hilderband JH (1999) A spectrophotometric investigation of the interaction of iodine with aromatic hydrocarbons. *J Am Chem Soc* 71:2703–2707
28. Szetli J (1985) Molecular entrapment and release properties of drugs by cyclodextrins. *Controlled drug Bio-availability*. Vol. 3, Wiley interscience publications, New York, pp 365–420